Pfizer, Inc. (PFE)

Wall Street analysts covering Pfizer, Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $28.64 — +8.9% versus the last price of $26.31. Targets reflect analyst opinion, not a guarantee.

42 members of Congress have disclosed trading PFE — 35 purchases and 43 sales worth an estimated $1.2M. Most recent disclosure: Feb 10, 2026.

PFE's own executives and directors have made 3 open-market purchases ($3.0M) and 2 sales ($134,661) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 12, 2026.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company website ↗

• P/E ratio (35.1) — how many dollars you pay for each $1 of PFE's yearly profit. That's a fairly normal range.
• ROE (5.01%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
• Profit margin (6.80%) — of every $1 in sales, this is what's left as profit after all costs.
• Dividend yield (6.46%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.